Latest Non-nucleoside reverse transcriptase inhibitors Stories

2008-07-17 09:01:20

YARDLEY, Pa., July 17 /PRNewswire/ -- Tibotec Pharmaceuticals Ltd. announced today that two major phase III efficacy trials examining TMC278, its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in treatment-naive adults with HIV-1, are now recruiting patients. The global trials will compare the efficacy, safety and tolerability of TMC278 (25 mg) once daily oral tablet versus efavirenz (EFV), each coadministered with a background regimen of two nucleoside/nucleotide...

2008-07-02 09:01:03

CytoDyn, Inc. (Pink Sheets: CYDY) has begun GMP manufacturing and humanization of Cytolin(C), a monoclonal antibody that uses the human immune system to control HIV infection. The murine version of this product, for which there is already considerable human experience, will be used for a fast, randomized, double-blind, placebo-controlled clinical trial to supplement the data from a previous Phase Ib/IIa study. Ordinarily, pristine proof-of-principle requires a Phase III study. However, in the...

2006-06-30 17:41:05

WASHINGTON (Reuters) - A three-in-one AIDS pill officials hope will make it easier for patients to stick with their treatments won U.S. clearance on Friday for use in a global relief plan. The drug, made by India's Aurobindo Pharma Ltd., received tentative Food and Drug Administration approval. The FDA endorsement makes the product available for purchase under President George W. Bush's effort to provide AIDS-fighting medicines in 15 countries. The new pill contains the active...

2006-06-30 15:38:13

WASHINGTON (Reuters) - India's Aurobindo Pharma Ltd. won tentative U.S. approval on Friday to sell a three-in-one HIV-fighting pill, a decision that makes the drug available for purchase under a global AIDS relief plan. The Food and Drug Administration said the pill includes the active ingredients in the drugs lamivudine, zidovudine and nevirapine.

2005-12-13 17:47:26

NEW YORK (Reuters Health) - Higher blood levels of the anti-HIV drug efavirenz confer an increased risk of mental problems, Spanish researchers report. Patients with blood levels above 2.74 micrograms/milliliter were at more than five-fold greater risk of central nervous system side effects than other patients, Dr. Felix Gutierrez of the Hospital General Universitario de Elche in Alicante and colleagues report. New research suggests as many as half of patients on long-term efavirenz...

2005-07-28 13:56:49

Two new studies support the hypothesis that combination antiretroviral drug therapy may reduce the risk of mother-to-child HIV transmission through breastfeeding, findings that could have significant implications in the developing world. Researchers in the first study found mothers pass antiretroviral medications on to their breastfeeding infants in concentrations high enough to prevent infection. The second study showed levels of HIV RNA in breast milk are lower in mothers taking...

Word of the Day
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).